Status:

RECRUITING

Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion

Lead Sponsor:

M.D. Anderson Cancer Center

Conditions:

Hematopoietic and Lymphoid Cell Neoplasm

Malignant Solid Neoplasm

Eligibility:

All Genders

18+ years

Phase:

EARLY_PHASE1

Brief Summary

This study investigates whether alteplase can help to improve pleural fluid drainage and dyspnea (breathlessness) in patients with non-draining malignant pleural effusion. Alteplase helps dissolve blo...

Detailed Description

PRIMARY OBJECTIVE: I. To evaluate dyspnea using the visual analog scale (VAS) scale at one week in patients with symptomatic septated malignant neoplasm of the pleural effusion (MPE) and a non-draini...

Eligibility Criteria

Inclusion

  • Referral to pulmonary services for inability to drain fully via IPC
  • Presence of a symptomatic septated pleural effusion
  • A pleural effusion of significant moderate to large volume based on:
  • Chest radiograph: effusion filling \>= 1/3 of the hemithorax, or
  • Computed tomography (CT)-scan: AP depth of the effusion \>= 1/3 of the AP dimension on the axial image superior to the hemidiaphragm, including atelectatic lung surrounded by effusion, or
  • Ultrasound: effusion spanning at least three intercostal spaces, with a \>= 3 cm in at least one intercostal space, while the patient sits upright
  • Age \> 18
  • Borg score \>= 3
  • Absence of a blocked IPC as demonstrated by a flush with 20 cc of saline x1 without resistance
  • Presence of septated effusion based on ultrasound (US) and chest CT

Exclusion

  • Inability to provide informed consent
  • Study subject has any disease or condition that interferes with safe completion of the study including:
  • Uncorrectable coagulopathy based on criteria followed by cardiopulmonary center for procedures.
  • Active bleeding
  • Known allergic reaction to thrombolytics
  • Pleural effusion is smaller than expected on bedside pre-procedure ultrasound
  • No septations and/or no loculations on bedside pre-procedure ultrasound
  • Patient is asymptomatic
  • Blocked IPC as determined by saline flush

Key Trial Info

Start Date :

August 17 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 2 2027

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06184321

Start Date

August 17 2023

End Date

February 2 2027

Last Update

December 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030